27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
An estimated two thirds of people living with Alzheimer’s disease or related dementias (ADRD) live and are cared for at home. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The model achieved and AUC of 0.72 [0.64, 0.81]. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A Doença de Alzheimer (DA) é a principal causa de demência no mundo, caracterizada por processos neurodegenerativos progressivos que comprometem cognição, comportamento e funcionalidade. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Women have twice the dementia risk compared with men. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Poly(ADP-ribosyl)ation (PARylation), a crucial post-translational modification, is catalyzed by ADP-ribosyltransferases (ARTs) and has significant implications in various cellular processes, including DNA damage response, cell signaling, and immune processes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of note, using large-scale transcriptome and chromatin profiling, we show that T cell shape microglia-specific metabolic plasticity in both genetic and epigenetic resolution. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). 5 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). 5 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is characterized by progressive accumulation of amyloid-β (Aβ) peptides, initiating a pathological cascade from soluble monomers to toxic oligomers, protofibrils, fibrils, and ultimately extracellular amyloid plaques that contribute to synaptic dysfunction and neuronal degeneration. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
LUMEN demonstrated strong performance in distinguishing dementia from normal cognition (AUROC=0.89) but moderate subtype differentiation (AUROC=0.66). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is a progressive neurodegenerative condition that affects the elderly population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a memory and cognitive function neurodegenerative disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is an irreversible brain condition that impairs memory and cognitive processes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a progressive brain disorder that leads to memory loss and a gradual decline in thinking and reasoning abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Effect size analysis proves the fact that the hybrid model produces statistically significant performance, as well as cases of clinically meaningful improvements over lightweight CNN baselines. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caregivers considered telemedicine useful, accessible, and safe, facilitating the continuity of care and strengthening the caregiver–professional relationship. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Across the literature, it is evident that health inequalities currently exist and exacerbate the disparities in the care of BAME dementia patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a progressive neurodegenerative disorder that represents a growing challenge to global health, especially in aging populations. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Future research should leverage perspectives of former caregivers to assist with improving outcomes for Black caregivers, thereby promoting health equity. [ Journal of Gerontological Nursing, 51 (6), 30–37.] 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In last two decades the growing life expectancy has spiralled the prevalence of neurogenerative disorder such as Dementia among elderly population posing a significant challenge to mental health globally. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Obstructive sleep apnea (OSA), a prevalent sleep-disordered breathing condition, is increasingly recognized as a modifiable risk factor for cognitive decline and dementia, including Alzheimer’s disease and vascular dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment (CI) is one of the most common causes of disability in the elderly. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our findings support apathy and APOE ε4 as robust predictors of conversion to MCI and ADD, and demonstrate novel associations between antidepressant use and conversion. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →